Article citationsMore>>

Tzortzis, V., Mitrakas, L., Gravas, S., Mamoulakis, C., Meissner, A., Kyriakou, D. and Melekos, M.D. (2009) Oral Phosphodiesterase Type 5 Inhibitors Alleviate Recurrent Priapism Complicating Thalassemia Intermedia: A Case Report. Journal of Sexual Medicine, 6, 2068-2071.
http://dx.doi.org/10.1111/j.1743-6109.2009.01285.x

has been cited by the following article:

• TITLE: Oral Phosphodiesterase Type 5 Inhibitors in Recurrent Priapism Complicating Thalassemia Intermedia: A Case Report

  AUTHORS: Davood Maleki

  KEYWORDS: PDE5is, Reccurent Priapism, Thalassemia Intermedia, PDE5is for Priapism, Gonadotropin-Releasing Hormone Agonist for Priapism

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.3 No.6, June 5, 2014

  ABSTRACT: Recurrent priapism is a rare, serious and difficult to treat complication of some hematological disorders, for which no standard therapy exists. This study reports a case of a 42-year-old man with thalassemia intermedia complicated by recurrent episodes of priapism. To prevent priapism recurrences, a trial of PDE5is use was initiated. One day after initiation of a PDE5i (25 mg sildenafil repeated every 8 hours), priapism was improved. For 3 weeks, the patient reported improvement, without experiencing any episodes of priapism and a normal physiologic erectile function. Four weeks after treatment he experienced priapism reoccurrence and doubling of the Sildenafil was not effective. Gonadotropin-releasing hormone agonist initiated and one week after initiatin of new drug he improved. He was free of priapism episodes for more than 2 years afterward. PDE5 deregulation seems to be an underling pathologic mechanism of recurrent priapism at least in thalassemia intermedia patients. It appears that PDE5is may have a role in the management of such patients and further testing in clinical trials is needed.